Products for Research Use Only

VTP50469 (mesylate)

CAT: 0804-HY-114162BSize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-114162BSize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
VTP50469 mesylate is a potent, and selective Menin-MLL1 inhibitor that effectively targets MLL-rearranged and NPM1c+ leukemia. VTP50469 mesylate selectively kills cell lines with MLL rearrangements and NPM1c+ mutations. VTP50469 mesylate displaces Menin from protein complexes and inhibits MLL's chromatin occupancy at specific genes, leading to significant changes in gene expression, differentiation, and apoptosis. VTP50469 demonstrates dramatic reductions in leukemia burden in patient-derived xenograft models of MLL-r acute myeloid leukemia and MLL-r acute lymphoblastic leukemia, with some mice remaining disease-free for over a year post-treatment.
CAS Number
2169919-27-9
UNSPSC
12352005
Target
Apoptosis; Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vtp50469-mesylate.html
Smiles
CS(=O)(O)=O.CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1OC2=CN=CN=C2N(C3)CC3(CC4)CCN4C[C@@H]5CC[C@H](CC5)NS(C)(=O)=O)=O.CS(=O)(O)=O
Molecular Formula
C34H55FN6O10S3
Molecular Weight
823.03
References & Citations
[1]A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products